Bangkok, Thailand, 27.04.2020
Roche Diagnostics joins the fight against COVID-19
- Combined total of 15,500 PPE and surgical masks presented to Siriraj Hospital to bolster protection against virus for medical personnel
Bangkok – 27 April 2020 - In light of the concerning spread of COVID-19 across the world, Roche Diagnostics (Thailand) Limited – led by Managing Director Pichetpong Srisuwankul and fellow employees – presented a contribution of medical equipment comprising 500 sets of WHO-standard personal protective equipment and 15,000 surgical masks to Siriraj Hospital. This donation was presented to the “Siriraj Against COVID-19” project with the goal of providing protection against the novel coronavirus to medical personnel working on the frontlines against COVID-19. Assoc. Prof. Visit Wamwanich, Ph.D., Director of Siriraj Hospital, and Prof. Sansanee Senawong, Ph.D., chief of the Immunology Department, Faculty of Medicine, Siriraj Hospital, were present to accept the contributions at the hospital on April 22, 2020.
Pichetpong Srisuwankul, Managing Director of Roche Diagnostics (Thailand) Limited, said, “Roche Diagnostics is a leading provider of in vitro diagnostics, and we are ready to contribute to the safety of medical personnel in order to enable them to perform to the best of their abilities. This is why we have decided to donate key equipment such as PPE and surgical masks to Siriraj Hospital, which is a major center in the fight against COVID-19. With a large number of incoming patients, both directly and transferred from other hospitals, Siriraj still requires a high number of medical equipment to prevent the disease from spreading to doctors, nurses, and other medical personnel in contact with patients. In addition to Siriraj Hospital, Roche Diagnostics intends to present additional donations of medical equipment to other hospitals in the country to help everyone overcome these challenging times together.”
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.